HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'

Executive Summary

The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn. 

You may also be interested in...

France In 2022: Pharmacy And Prevention Trends Drive Double-Digit OTC Growth

Consumers visiting pharmacies for preventative health products like food supplements drove strong growth in France's consumer healthcare market in 2022. To build on this success, the country's OTC manufacturers' association, NèreS, is calling for a national self-care strategy that would promote pharmacists as the go-to healthcare professionals for self-care. 

Surprise, Skepticism And Scorn: Reaction To Rumored Haleon Interest In Sanofi CHC

Analysts share their thoughts on reports that Haleon is interested in acquiring Sanofi Consumer Healthcare to enhance its market leading position.

Zentiva Grows In Italy With Acquisition Of Sanofi OTC Brands

Zentiva adds the Zerinol and Schoum Solution OTC brands to its Italian portfolio as Sanofi continues to offload non-core consumer health brands to focus on its priority categories.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts